ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
Delayed Nasdaq  -  05/27 04:00:01 pm EDT
127.77 USD   +1.73%
05/25TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-25-2022 10:00 AM
CI
05/24Alnylam Pharmaceuticals' Phase 3 Study Shows Improvement in Exploratory Endpoints in Patients With Rare Genetic Disease PH1
MT
05/24Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Decline Pre-Bell Friday

01/21/2022 | 09:18am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALNYLAM PHARMACEUTICALS, INC. 1.73% 127.77 Delayed Quote.-25.93%
ATHERSYS, INC. 9.22% 0.2108 Delayed Quote.-76.65%
NASDAQ COMP. 3.33% 12131.13 Real-time Quote.-22.46%
REGULUS THERAPEUTICS INC. 12.52% 0.31 Delayed Quote.-1.59%
All news about ALNYLAM PHARMACEUTICALS, INC.
05/25TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, M..
CI
05/24Alnylam Pharmaceuticals' Phase 3 Study Shows Improvement in Exploratory Endpoints in Pa..
MT
05/24Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patien..
BU
05/24Alnylam Pharmaceuticals, Inc. Presents New Results from the ILLUMINATE-C Phase 3 Study ..
CI
05/24TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at H.C. Wainwright Global Investment C..
CI
05/23ALNYLAM PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Finan..
AQ
05/23Alnylam Pharmaceuticals Says Vutrisiran Drug Candidate Showed Clinical Benefit to Amylo..
MT
05/23Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Ph..
BU
05/23Alnylam Pharmaceuticals, Inc. Announces New Positive Results from an 18-Month Analysis ..
CI
05/18Alnylam Announces Health Canada Authorization of OXLUMO™ (lumasiran), the First a..
AQ
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 1 089 M - -
Net income 2022 -836 M - -
Net cash 2022 1 216 M - -
P/E ratio 2022 -18,9x
Yield 2022 -
Capitalization 15 436 M 15 436 M -
EV / Sales 2022 13,1x
EV / Sales 2023 8,78x
Nbr of Employees 1 665
Free-Float 99,4%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 127,77 $
Average target price 204,23 $
Spread / Average Target 59,8%
EPS Revisions
Managers and Directors
Yvonne L. Greenstreet Chief Executive Officer & Director
Akshay K. Vaishnaw President
Jeffrey V. Poulton Chief Financial Officer & Executive Vice President
Michael W. Bonney Independent Director
Pushkal P. Garg Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ALNYLAM PHARMACEUTICALS, INC.-25.93%15 436
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478